Labcorp gets FDA approval for PGDx elio tissue complete CDx in BRAF-mutated melanoma
Labcorp Holdings Inc. (NYSE: LH) announced on August 10, 2026 that the U.S. Food and Drug Administration has approved PGDx elio tissue complete CDx as a companion diagnostic for identifying melanoma patients whose tumors carry BRAF V600E or BRAF V600K mutations and who may benefit from FDA-approved BRAF inhibitors or approved BRAF and MEK inhibitor
